SCHEMBL259993

SCHEMBL259993

O=C1Nc2ccc(CN3CCOC3=O)cc2/C1=C/c1cc(CCN2CCCC2)c[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.52
MET P08581 1/20 0.52
FGFR2 P21802 1/20 0.52
FGFR3 P22607 1/20 0.52
AXL P30530 1/20 0.52
PDPK1 O15530 4/20 0.44
AKT2 P31751 3/20 0.44
FLT3 P36888 4/20 0.39
PDGFRB P09619 4/20 0.39
KDR P35968 4/20 0.39
CSF1R P07333 1/20 0.39
PDGFRA P16234 1/20 0.39
FLT1 P17948 1/20 0.39
KIT P10721 2/20 0.38
NTRK1 P04629 1/20 0.38
PAK1 Q13153 3/20 0.37
PIM1 P11309 2/20 0.37
PIM2 Q9P1W9 2/20 0.37
TLK2 Q86UE8 1/20 0.36
PSEN1 P49768 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL259994 1.00 FGFR1 (0.52) FGFR1METFGFR2FGFR3AXL
SCHEMBL1225472 0.94 FGFR1 (0.59) FGFR1METFGFR2FGFR3AXL
SCHEMBL1225471 0.94 FGFR1 (0.59) FGFR1METFGFR2FGFR3AXL
Hydrochloric Acid SCHEMBL260986 0.93 FGFR1 (0.59) FGFR1METFGFR2FGFR3AXL
Hydrochloric Acid SCHEMBL260987 0.93 FGFR1 (0.59) FGFR1METFGFR2FGFR3AXL
SCHEMBL1225440 0.92 FGFR1 (0.61) FGFR1METFGFR2FGFR3AXL
SCHEMBL1225437 0.92 FGFR1 (0.61) FGFR1METFGFR2FGFR3AXL
Hydrochloric Acid SCHEMBL260366 0.91 FGFR1 (0.60) FGFR1METFGFR2FGFR3AXL
Hydrochloric Acid SCHEMBL260365 0.91 FGFR1 (0.60) FGFR1METFGFR2FGFR3AXL
SCHEMBL1162294 0.91 FGFR1 (0.60) FGFR1METFGFR2FGFR3AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653073-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2014-02-18 US disclosed
US-20130331380-A1 DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2013-12-12 US disclosed
US-8541412-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2013-09-24 US disclosed
US-8133889-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-03-13 US disclosed
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-02-23 US disclosed
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130331380-A1 DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CYP11B1, SDHA, CYP11B2 FGFR1 875/4885MET 2084/4885FGFR2 2322/4885
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 FGFR1 875/4885MET 2084/4885FGFR2 2322/4885
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 FGFR1 875/4885MET 2084/4885FGFR2 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.